TEAM

leadership & Directors

FendX Management

The FendX Technologies Inc. management team has significant leadership experience in developing and launching products globally, expertise in finance, business development, capital markets, growing businesses and serving as management and directors of public companies.

With this proven track record, we are well positioned to successfully develop and commercialize products globally.

Our team

Dr. Carolyn Myers

President & CEO

Andrea Mulder

Chief Operating Officer

Board of Directors

Dr. Mark Landy

Director

prakash gowd

Director

Dr. Carolyn Myers

President & CEO

Dr. Carolyn Myers

Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading healthcare businesses. Dr. Myers is currently CEO of FendX Technologies Inc. and a Principal of Bioensemble LLC where she works closely with numerous start-ups and small pharma companies to assist them in developing their business strategy and planning. Her previous executive positions include Vice President International Business Development and Alliance Management at Allergan PLC, President of Dey Laboratories and President of Mylan Technologies Inc. Prior to serving in these roles, Dr. Myers served in various management positions in sales and marketing at Pharmacia Corporation., now a part of Pfizer, Inc. Dr. Myers earned her PhD in genetics from the University of British Columbia and her MBA from Rutgers University.

Dr. Myers is a member of the board of directors of publicly held Mayne Pharma and Hyloris Pharmaceuticals, a Steering Committee Member of Mid Atlantic Bio Angels, a Healthcare Committee Member of Golden Seeds Angels, and a Member of the Licensing Executive’s Society.

Andrea Mulder

Chief Operating Officer

Dr. Carolyn Myers

Andrea Mulder, BPHE, MBA is the COO of FendX Technologies Inc. and an accomplished senior commercial healthcare executive with experience in new product development and leading pre-launch to launch sales, marketing and market access strategies for several multinational biotechnology/pharmaceutical companies in Canada. She has significant knowledge across multiple therapeutic areas including infectious disease, immunology, neurology, respiratory and oncology and has been an active member of Global and Canadian leadership teams at: Eisai Canada, Sunovion, Ipsen, Celgene, GlaxoSmithKline, Roche, Johnson and Johnson and Pfizer. Andrea Mulder earned her degree at the University of Toronto in Health Sciences (BPHE) and her EMBA in Global Leadership at the University of Fredericton, Canada.

In her spare time, Andrea Mulder volunteers at several patient associations including the Canadian Epilepsy Alliance (CEA), MS Society (MS) and the Canadian Cancer Society (CCS).

Dr. Mark Landy

Director

Dr. Carolyn Myers

Dr. Mark Landy is an experienced business leader and entrepreneur. He is the Founding Principal of the Amadiba Group, an ideation, consulting and crisis management company and serves as the CEO of one of its ideated companies, JeniMed, a technology company developing a digital physician assistant to improve patient communication, compliance and care.

From 2016 to 2019, Dr. Landy served in increasingly senior positions at MiMedx, including Executive Vice President & Chief Strategy Officer. In 2018, Dr. Landy was appointed to the Company’s “New Leadership Team” which was tasked with resolving government investigations, financial restatement, and restoring culture, integrity, trust, and moral. As CSO Dr. Landy held chief leadership of Strategy, Research & Development, Quality and Regulatory Assurance, Market Access (national accounts, reimbursement, health policy), Clinical Affairs, Medical Affairs, Regulatory Affairs, Medical Education, Marketing, Communication, Business Development, and International.

Previously Dr. Landy served as President & Chief Executive Officer and a Director of MIV Therapeutics, a drug delivery company focused on developing, manufacturing and commercializing drug eluting stents and other implantable drug delivery systems. Dr. Landy has also held senior level positions on both the buy-side and sell-side at leading financial firms including Investor AB, Leerink Swann & Company and Susquehanna Financial Group.

He received a Bachelor of Dental Science (BDS) degree from the University of Witwatersrand in Johannesburg, South Africa and a Bachelor of Business Administration degree from The Wharton School of Business in Philadelphia, PA.

Experienced business leader and entrepreneur. Founding Principal of the Amadiba Group and serves as CEO of JeniMed. Previously served as Executive Vice President & Chief Strategy Officer at MiMedx and President, CEO and Director of MIV Therapeutics. Brings significant capital markets expertise having also held senior positions on both the buy-side and sell-side at leading financial firms including Investor AB, Leerink Swann & Company and Susquehanna Financial Group. Holds a Bachelor of Dental Science (BDS) degree from University of Witwatersrand and BBA degree from The Wharton School of Business.

prakash gowd

Director

Dr. Carolyn Myers

Prakash Gowd brings over 25 years of experience in executive management, strategic business analysis, corporate development, financing, and capital markets focused on the healthcare and biopharma sectors. 

He is currently Senior Vice President, Corporate Development at Novamind Inc., a public mental healthcare and psychedelic medicine company, where he leads corporate strategy, business development and M&A initiatives.  He is also a strategic advisor to N-Zyme Biomedical, a clinical-stage drug development company.  Previously, Mr. Gowd was President and Co-founder of Lobo Genetics, a genetic testing company, where he played pivotal roles in the development of the company and its evolution through challenging conditions, culminating in the sale to a third party. 

His extensive capital markets experience was attained through multiple senior level equity research roles with CIBC World Markets, National Bank Financial, and Canaccord Capital, where he focused exclusively on financing and investments in healthcare, biotech, medical device, and specialty pharma companies. 

Mr. Gowd held progressive positions in commercial operations at GlaxoSmithKline and specialized in marketing and new product development consulting for clients in the pharmaceutical industry.  He served as Audit Chair and Director of Isotechnika Pharma Inc., the predecessor company to Aurinia Pharmaceuticals. 

Mr. Gowd holds an MBA from McGill University, a BSc Pharmacy from the University of British Columbia, and a Chartered Director designation.

Prakash Gowd brings over 25 years of experience in executive management, corporate development, finance, and capital markets in the healthcare and biopharma sectors.  

He is currently Chief Operating Officer at Novamind Inc., a mental healthcare and psychedelic medicine company, where he oversees the company’s clinics and research operations.  He also serves as Strategic Advisor to N-Zyme Biomedical. Previously, Mr. Gowd was President and Co-Founder of Lobo Genetics, a genetic testing company acquired by Entheon Biomedical. 

His extensive capital markets experience included senior level equity research roles with CIBC World Markets, National Bank Financial, and Canaccord Capital, where he focused on financing and investments in healthcare, biotech, medical device, and specialty pharma.  Mr. Gowd held progressive positions in commercial operations at GlaxoSmithKline, and specialized in pharmaceutical marketing and new product development.  He served as Audit Chair and Director of Isotechnika Pharma Inc., the TSX-listed predecessor to Aurinia Pharmaceuticals.  

Mr. Gowd holds an MBA from McGill University, a BSc Pharmacy from the University of British Columbia, and a Chartered Director designation.